CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
Melero I, Sanmamed M, Glez-Vaz J, Luri-Rey C, Wang J, Chen L. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery 2022, 13: 552-569. PMID: 36576322, DOI: 10.1158/2159-8290.cd-22-1029.Peer-Reviewed Original ResearchConceptsAnti-CD137 monoclonal antibodiesT cell antitumor immunitySevere liver inflammationTolerable safety profileCancer immunotherapy strategiesNatural killer lymphocytesSingle-agent activityNon-Hodgkin lymphomaEarly phase trialsChimeric antigen receptorCD137 agonistsEnhanced CD8Unacceptable toxicityAntitumor immunityLiver inflammationImmunotherapy strategiesSafety profileCancer immunotherapyKiller lymphocytesClinical activityAgonist antibodyPharmacodynamic activityMouse modelCD137Costimulatory receptors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply